Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective longitudinal study assessing the hemorrhage risk of direct oral anticoagulants in real-world Venous Thromboembolism patients in real world

Next Previous
Trial Profile

A retrospective longitudinal study assessing the hemorrhage risk of direct oral anticoagulants in real-world Venous Thromboembolism patients in real world

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions

Most Recent Events

  • 18 Aug 2021 New trial record
  • 01 Aug 2021 Results (N= 41830), of a comparative analysis of Apixaban versus Rivaroxaban published in the Thrombosis Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top